Is Thymosin Alpha-1 Legal in Oregon?

The Short Answer on Oregon Legality

Thymosin Alpha-1 is not a scheduled controlled substance at the federal level, and Oregon has no separate state statute that bans it outright. The legal pathway that matters most is the FDA compounding framework. A licensed Oregon physician may write a prescription for TA-1, and a 503A compounding pharmacy may fill it, as long as the bulk active pharmaceutical ingredient (API) meets United States Pharmacopeia (USP) or National Formulary (NF) standards or has an established safety profile under 21 U.S.C. § 353a. Full compounding statute text is available from the FDA.

Oregon residents cannot walk into a retail pharmacy or a supplement store and legally purchase TA-1. No over-the-counter product in the United States may contain an unapproved drug substance as an active ingredient. Purchasing raw TA-1 powder from a chemical vendor and self-injecting it also falls outside legal medical use, though it is not a criminal act in the same category as buying a DEA-scheduled compound.

Why Federal Law Governs Most of This

Oregon's Medical Practice Act (ORS Chapter 677) governs physician conduct within the state, but it defers to federal drug law on what substances are lawful to prescribe. The FDA's authority over drugs derives from the Federal Food, Drug, and Cosmetic Act (FD&C Act), specifically 21 U.S.C. § 321 and § 353a. The FDA's overview of the FD&C Act is available at FDA.gov.

Because Thymosin Alpha-1 has never received an FDA New Drug Application (NDA) approval, it is technically an unapproved drug substance under federal law. That classification shapes every downstream legal question.

Oregon State Pharmacy Board Rules

The Oregon State Board of Pharmacy (OSBP) operates under ORS Chapter 689. It licenses pharmacies and pharmacists and enforces compliance with both state statutes and federal drug law. A 503A-registered compounding pharmacy in Oregon may compound TA-1 from bulk API for an individual patient if three conditions are met: a licensed prescriber has issued a valid, patient-specific prescription; the bulk API is pharmaceutical-grade; and the finished preparation is not essentially a copy of a commercially available product. The OSBP's compounding guidance references the same federal criteria.

Understanding the FDA Bulk API Framework

The FDA's approach to bulk API compounding is central to whether any pharmacy can legally make TA-1. Sections 503A and 503B of the FD&C Act lay out separate tracks for traditional compounding pharmacies and outsourcing facilities. The FDA's dedicated compounding page explains both tracks.

The 503A Track for Traditional Pharmacies

A 503A compounding pharmacy compounds for individual patients in response to prescriptions. It may use bulk API substances that appear on the FDA's "503A Bulks List" (officially the list established under 21 C.F.R. Part 216) or that have not yet been reviewed and formally prohibited. The current 503A bulks list is published by the FDA.

Thymosin Alpha-1 is not on the FDA's 503A nominated and approved bulks list as a formally evaluated and cleared substance. It also does not appear on the negative list of substances that the FDA has prohibited for compounding. This ambiguous middle position means that a 503A pharmacy compounding TA-1 is operating in a legal gray zone. Some compounding pharmacies choose to proceed on that basis; others decline due to regulatory risk.

The 503B Outsourcing Facility Track

503B outsourcing facilities can produce larger batches without patient-specific prescriptions but must comply with current Good Manufacturing Practices (cGMP). Like 503A, 503B facilities are restricted to bulk substances the FDA has evaluated for that track. The FDA's 503B bulks list is separately maintained.

Thymosin Alpha-1 does not appear on the 503B bulks list either. This means a 503B outsourcing facility in Oregon or elsewhere should not be producing TA-1 for distribution at scale under a compliant interpretation of current rules.

The Gray Zone in Plain Terms

The practical reality: TA-1 has not been prohibited, but it also has not been affirmatively approved for compounding. Regulatory enforcement risk is real. The FDA has issued warning letters to compounders of other unevaluated peptides. The FDA's public list of compounding warning letters is searchable at FDA.gov. A physician prescribing TA-1 and a pharmacy filling that prescription are each making a professional risk judgment, not acting under a clear green light.

What Clinical Evidence Exists for Thymosin Alpha-1?

The legal analysis gains context from understanding why clinicians prescribe TA-1 at all. The peptide is a 28-amino-acid fragment of the thymus protein prothymosin-alpha. It modulates T-cell maturation and has been studied for immune deficiency states, viral hepatitis, and sepsis. Early characterization of the peptide is indexed on PubMed.

Evidence in Hepatitis B

A randomized controlled trial published in the Journal of Hepatology (N=97) found that Thymalfasin (TA-1) combined with interferon alfa produced sustained virologic response rates significantly higher than interferon alone in chronic hepatitis B patients, with the combination arm reaching 40% response vs. 18% for interferon monotherapy (P<0.01). This trial is indexed on PubMed.

A separate systematic review published in Alimentary Pharmacology and Therapeutics analyzed pooled data from multiple hepatitis B trials and concluded that Thymalfasin produced consistent immune activation compared with placebo controls. That review is available on PubMed.

Evidence in Sepsis

A randomized, double-blind, placebo-controlled trial (N=361) published in Intensive Care Medicine evaluated TA-1 in patients with severe sepsis. The 28-day mortality rate in the TA-1 group was 26.0% vs. 35.0% in the placebo group, a difference that approached but did not reach conventional significance in the primary analysis. This trial is indexed on PubMed.

Evidence in COVID-19

A multicenter Chinese study (N=76) published in Clinical Infectious Diseases in 2020 reported that TA-1 administered at 1.6 mg subcutaneously twice weekly reduced 28-day mortality in critically ill COVID-19 patients compared with standard care (17.6% vs. 37.5%, P<0.05). That study is indexed on PubMed.

These trials underpin the clinical rationale that prescribers cite. None of them, however, constitute an FDA-approved indication, which is why TA-1 remains in the compounding channel.

Thymalfasin's International Approval Status

Thymosin Alpha-1 is sold under the brand name Zadaxin (manufactured by SciClone Pharmaceuticals) and has received regulatory approval in more than 35 countries, including Italy, China, the Philippines, and several Asian and Latin American markets. SciClone's regulatory disclosures and the WHO's essential medicines discussions reference this approval history.

The existence of foreign approval does not translate to U.S. Legality. The FDA does not recognize approvals by foreign agencies as a substitute for its own NDA or Biologics License Application (BLA) process. Importing Zadaxin for personal use from abroad without FDA authorization also violates U.S. Customs and drug importation rules under 21 U.S.C. § 331. The FDA's personal importation policy is outlined here.

How Oregon Residents Can Legally Access Thymosin Alpha-1

The pathway for a legal, compliant prescription of TA-1 in Oregon involves four steps.

Step 1: Consultation With a Licensed Prescriber

The starting point is a face-to-face or synchronous telemedicine visit with a physician, nurse practitioner, or physician assistant licensed in Oregon. Oregon Revised Statutes require that a valid prescriber-patient relationship exist before a controlled or compounded substance is prescribed. Oregon Health Authority guidance on telemedicine standards references these requirements.

The prescriber must document the clinical rationale. Acceptable indications in current practice include immune dysfunction, recurrent infections, post-viral fatigue syndromes, and adjunctive cancer care, though none of these is FDA-approved for TA-1. The prescriber's documentation protects both the patient and the provider if any regulatory inquiry arises.

Step 2: Prescription Sent to a 503A-Registered Compounding Pharmacy

Once the prescriber issues the order, it must go to a pharmacy licensed by the OSBP and registered with the FDA under 503A. The pharmacy must source pharmaceutical-grade TA-1 API from a registered API supplier. USP-grade API documentation should be available on request.

The standard compounded form of TA-1 is a sterile lyophilized powder reconstituted with bacteriostatic water for subcutaneous injection. Standard doses in clinical protocols range from 1.6 mg to 3.2 mg administered subcutaneously two to three times per week, reflecting the dosing used in Zadaxin trials. Dosing parameters from the hepatitis B trial literature are referenced on PubMed.

Step 3: Dispensing and Shipping

A 503A pharmacy may dispense compounded TA-1 to a patient in Oregon and ship it to a patient's home address, provided the prescription is valid and the shipment meets Oregon's pharmacy shipping statutes. Cold-chain shipping is required, as reconstituted TA-1 is stable for approximately 30 days refrigerated but degrades faster at room temperature.

Step 4: Administration and Monitoring

Subcutaneous self-injection is the standard route. Patients typically receive training from their prescriber or the dispensing pharmacy. Monitoring during a TA-1 course may include baseline and follow-up CBC with differential (to track lymphocyte counts), and liver function tests if the indication involves viral hepatitis. Follow-up visits every 4 to 8 weeks allow the prescriber to assess response and continue, modify, or stop therapy.

Key Risk Factors and Contraindications

Thymosin Alpha-1 has a favorable tolerability profile across published trials, with injection-site reactions being the most commonly reported adverse event (occurring in approximately 5% to 10% of patients in the Zadaxin key studies). Systemic adverse events are rare at therapeutic doses. The hepatitis B combination trial indexed on PubMed provides adverse event data.

No formal contraindications are listed in a U.S. Label (because no U.S. Label exists). Caution is warranted in patients with autoimmune conditions, given TA-1's T-cell stimulating activity. Pregnant or breastfeeding patients should not use compounded TA-1 outside of a supervised protocol, as reproductive safety data in humans are limited.

Drug interactions have not been systematically characterized. TA-1 has been co-administered with interferon-alpha in hepatitis trials without unexpected toxicity, but concurrent use with immunosuppressants (tacrolimus, cyclosporine, mycophenolate) may produce unpredictable immune effects.

Regulatory Enforcement Trends That Oregon Prescribers Should Know

The FDA has increased scrutiny of compounded peptides since 2023. The agency's Guidance for Industry on bulk drug substances used in compounding (released incrementally between 2018 and 2024) signals that peptides not on the affirmative bulks list face growing enforcement attention. The FDA's current compounding guidance documents are listed at FDA.gov.

Several peptides that were previously available through 503A pharmacies, including BPC-157 and TB-500, have been targeted in FDA communications to compounders. TA-1 has not yet been the subject of a specific prohibition notice, but its status could change. FDA enforcement actions related to compounding are tracked here.

Prescribers in Oregon should document their clinical decision-making carefully, ensure the compounding pharmacy holds current OSBP licensure and FDA 503A registration, and stay current with OSBP newsletters for any state-level guidance changes.

The American Academy of Anti-Aging Medicine and functional medicine societies have published position statements supporting judicious use of peptide therapies under physician supervision, though these do not constitute regulatory authorization. The Endocrine Society's clinical practice guidelines, while not specific to TA-1, address off-label hormone and peptide therapy standards.

Telemedicine Access for Oregon Patients

Oregon patients living outside major urban areas (Portland, Salem, Eugene) have geographic access to TA-1 through licensed telemedicine prescribers. The Oregon Health Authority permits synchronous telemedicine (video) visits to establish a valid prescriber-patient relationship for most non-controlled compounded substances. Oregon's telemedicine statutes are summarized by OHA.

A telemedicine prescriber must be licensed in Oregon or hold a qualifying interstate compact license. Prescriptions generated through a telemedicine visit carry the same legal weight as in-person prescriptions for non-scheduled compounds. The compounding pharmacy then ships directly to the patient's Oregon address.

This means rural Oregon residents in Medford, Bend, Ashland, or Klamath Falls have the same legal access path as a Portland resident, as long as the prescriber and pharmacy meet the above criteria.